Skip to main content

Advertisement

SpringerLink
Log in

Improving Treatment Adherence in Schizophrenia

  • Schizophrenia and Other Psychotic Disorders (J Csernansky, Section Editor)
  • Published:
Current Treatment Options in Psychiatry Aims and scope Submit manuscript

An Erratum to this article was published on 11 June 2016

Opinion statement

Poor treatment adherence among people with schizophrenia is associated with several negative outcomes, including increased risk of symptom relapse, persistent psychotic symptoms, frequent hospitalizations, increased emergency room use, and suicide attempts. In addition, the benefits of treatment adherence in this population include improved quality of life and reduced treatment costs. Clearly, feasible and effective strategies to maximize treatment adherence are essential. Interventions to promote adherence to medications include environmental cues and supports, technology-based interventions, medication management coordinators, adherence therapy, and the use of long-acting injectable medications. Interventions to promote continuity of care between inpatient and outpatient treatment include Assertive Community Treatment, transitional care models, and the use of peer support personnel as care navigators. Transitional care models have also demonstrated effectiveness in promoting adherence to primary care follow-up among people with schizophrenia and comorbid medical illnesses. In the context of complex treatment regimens for psychiatric and medical illnesses, thorough education and skill development on illness management and health promotion, tailored to the unique learning needs of PWS, are essential. In addition, more research is needed to address understanding of medical illnesses, the accuracy in which people with schizophrenia implement activities for medical illness self-management, and development of strategies to promote engagement in health promotion activities among people with schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12:216–26. This comprehensive review compares rates of medication adherence across several chronic medical conditions and psychotic disorders. News flash: There’s room for improvement in all specialties. It also provides an exhaustive list of potential barriers to medication adherence, along with strategies for clinicians to address adherence problems in their patients with psychosis.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for healthcare reform. N Engl J Med. 2010;362:1553–5.

    Article  CAS  PubMed  Google Scholar 

  3. Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3:200–18.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry. 2015;15:189.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hayhurst KP, Drake RJ, Massie JSA, et al. Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry. 2014;29:191–6.

    Article  CAS  PubMed  Google Scholar 

  6. Jiang Y, Ni W. Estimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalization. Pharmacotherapy. 2015;35:813–22.

    Article  PubMed  Google Scholar 

  7. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009; 70(suppl. 4): 1–48

  8. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892–909.

    Article  PubMed  Google Scholar 

  9. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.

    Article  CAS  PubMed  Google Scholar 

  10. Kim E, Gupta S, Bolge S, Chen CC, Whitehead R, Bates JA. Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey. J Med Econ. 2010;13:185–92.

  11. Moritz S, Hünsche A, Lincoln TM. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms. Eur Neuropsychopharmacol. 2014;24:1745–52.

    Article  CAS  PubMed  Google Scholar 

  12. Czobor P, Van Dorn RA, Citrome L, Kahn RS, Fleischhacker WW, Volavka J. Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Psychopharmacol. 2015;25:1158–66.

    CAS  Google Scholar 

  13. Beck EM, Cavelti M, Kvrgic S, Kleim B, Vauth R. Are we addressing the “right stuff” to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophr Res. 2011;132(1):42–9.

    Article  PubMed  Google Scholar 

  14. McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leal R, Rössler W, et al. The therapeutic relationship and adherence to antipsychotic medication in schizophrenia. PLoS One. 2012;7:e36080. doi:10.1371/journal.pone.0036080.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Misdrahi D, Petit M, Blanc O, Bayle F, Llorca PM. The influence of therapeutic alliance and insight on medication adherence in schizophrenia. Nordic J Psychiatry. 2012;66:49–54.

    Article  Google Scholar 

  16. Sapra M, Weiden PJ, Schooler NR, et al. Reasons for adherence and nonadherence: a pilot study comparing first- and multi-episode schizophrenia patients. Clin Schizophr Relat Psychoses. 2014;4:199–206.

  17. Velligan D, Mintz J, Maples N, et al. A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. Schizophr Bull. 2012;39:999–1007.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lafeuille MH, Grittner AM, Fortier J, et al. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics. Am J Health Syst Pharm. 2015;72:378–89.

    Article  PubMed  Google Scholar 

  19. Chien WT, Mui JHC, Cheung EFC, Gray R. Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial. Trials. 2015;16:270.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Schulz M, Gray R, Spiekermann A, Abderhalden C, Behrens J, Driessen M. Adherence therapy following an acute episode of schizophrenia: a multi-centre randomised controlled trial. Schizophr Res. 2013;146:59–63.

    Article  PubMed  Google Scholar 

  21. Sajatovic M, Levin J, Raminez LF, et al. Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2013;74:1249–55.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Beadles CA, Ellis AR, Lichstein JC, et al. First outpatient follow-up after psychiatric hospitalization: does one size fit all? Psychiatr Serv. 2015;66:364–72.

    Article  PubMed  Google Scholar 

  23. Hamilton JE, Rhoades H, Galvez J, et al. Factors differentially associated with early readmission at a university teaching psychiatric hospital. J Eval Clin Pract. 2015. doi:10.1111/jep.12335.

    PubMed  Google Scholar 

  24. Hanrahan NP, Solomon P, Hurford MO. A pilot randomized control trial: testing a transitional care model for acute psychiatric conditions. J Am Nurses Assoc. 2014;20:315–27.

    Google Scholar 

  25. Solomon P, Hanrahan NP, Hurford M, DeCesaris M, Josey L. Lessons learned from implementing a pilot RCT of transitional care model for individuals with serious mental illness. Arch Psychiatr Nurs. 2014;28:250–5.

    Article  PubMed  Google Scholar 

  26. Maples NJ, Copeland LA, Zeber JE, et al. Can medication management coordinators help improve continuity of care after psychiatric hospitalization? Psychiatr Serv. 2012;63:554–60.

    Article  PubMed  Google Scholar 

  27. Bond GR, Drake RE. The critical ingredients of assertive community treatment. World Psychiatry. 2015;14:240–2.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Valenstein M, McCarthy JF, Ganoczy D, et al. Assertive community treatment in Veterans Affairs settings: impact on adherence to antipsychotic medication. Psychiatr Serv. 2013;64:445–51.

    Article  PubMed  Google Scholar 

  29. Ahmed AO, Doane NJ, Mabe PA, et al. Peers and peer-led interventions for people with schizophrenia. Psychiatr Clin N Am. 2012;35:699–715.

  30. Boardman G, McCann T, Kerr D. A peer support programme for enhancing adherence to oral antipsychotic medication in consumers with schizophrenia. J Adv Nurs. 2014;70:2293–302.

    Article  PubMed  Google Scholar 

  31. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77.

    Article  Google Scholar 

  32. Gittelman M. Why are the mentally ill dying? Int J Ment Health. 2008;37:3–12.

    Article  Google Scholar 

  33. Manderscheid RW. Premature death among state mental health agency consumers: assessing progress in addressing a quiet tragedy. Int J Public Health. 2009;54:S7–8.

    Article  Google Scholar 

  34. Schoepf D, Uppal H, Potluri R, Heun R. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci. 2014;264:3–28.

    Article  PubMed  Google Scholar 

  35. Ward M, Druss B. Diabetes and psychotic disorders 1. The epidemiology of diabetes in psychotic disorders. The Lancet Psychiatry. 2015;2:431–51.

    Article  PubMed  Google Scholar 

  36. Hensel JM, Flint AJ. Addressing the access problem for patients with serious mental illness who require tertiary medical care. J Health Care Poor Underserved. 2015;26:35–48. This article examines adherence in the context of access to care issues for PWS who are in need of medical care. The description of competent and incompetent choice to adhere to medical treatment is illuminating and helpful as a guide for psychiatric and medical providers to assess the ability of PWS to understand the ramifications of treatment adherence.

    Article  PubMed  Google Scholar 

  37. Cunningham C, Peters K, Mannix J. Physical health inequities in people with severe mental illness: identifying initiatives for practice change. Issues Mental Health Nurs. 2013;34:855–62.

    Article  Google Scholar 

  38. McKibbin CL, Kitchen KA, Wykes TL, Lee AA. Barriers and facilitators of a healthy lifestyle among persons with serious and persistent mental illness: perspectives of community mental health providers. Community Ment Health J. 2014;50:566–76.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Gorczynski P, Patel H, Ganguli R. Adherence to diabetes medications in individuals with schizophrenia: a systematic review of rates and determinants of adherence. Clin Schizophre Relat Psychoses. 2014. doi:10.3371/CSRP.GOPA.013114.

    Google Scholar 

  40. Boaz TL, Becker MA, Andel R, Van Dorn R, Choi J, Sikirica M. Risk factors for early readmission to acute care for persons with schizophrenia taking antipsychotic medications. Psychiatr Serv. 2013;64:1225–9.

    Article  PubMed  Google Scholar 

  41. Jackson C, DuBard A, Swartz M, Mahan A, et al. Readmission patterns and effectiveness of transitional care among Medicaid patients with schizophrenia and medical comorbidity. N C Med J. 2015;76(4):219–26. This important study addresses transitional care for people with comorbid schizophrenia and medical illnesses. It underscores the importance of distributing multidisciplinary care management resources based on patient need, timely identification of eligible patients following a psychiatric hospitalization discharge, and the benefit of transitional care above and beyond existing intensive resource interventions, such as ACT.

    PubMed  Google Scholar 

  42. Jackson C, Trygstad TK, DeWalt DA, DuBard CA. Transitional care cut hospital readmissions for North Carolina Medicaid patients with complex chronic conditions. Health Aff. 2013;32(8):1407–15.

    Article  Google Scholar 

  43. Findlay LJ, El-Mallakh P, Howard PB, Hatcher J, Clark JJ. Health behavior decision-making among African-American adults diagnosed with schizophrenia. Issues Mental Health Nurs. 2015;37:493–504.

    Article  Google Scholar 

  44. Bonds DE, Miller ME, Dudl J, et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: secondary analysis of the ACCORD clinical trial data. BMC Endocr Disord. 2012;12:5. doi:10.1186/1472-6823-12-5.

  45. El-Mallakh P. Evolving self-care in individuals with schizophrenia and diabetes mellitus. Arch Psychiatr Nurs. 2006;20:55–64.

    Article  PubMed  Google Scholar 

  46. El-Mallakh P. Doing my best: poverty and self-care in individuals with schizophrenia and diabetes mellitus. Arch Psychiatr Nurs. 2007;21:49–61.

    Article  PubMed  Google Scholar 

  47. Cañas F, Alptekin K, Azorin JM, et al. Improving treatment adherence in your patients with schizophrenia: the STAY initiative. Clin Drug Investig. 2013;33:97–107.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Nursing, University of Kentucky, 315 College of Nursing Building, #547, Lexington, KY, 40536-0232, USA

    Peggy El-Mallakh PhD, RN, PMHNP-BC & Jan Findlay PhD, RN, PMHNP-BC

Authors
  1. Peggy El-Mallakh PhD, RN, PMHNP-BC
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Findlay PhD, RN, PMHNP-BC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peggy El-Mallakh PhD, RN, PMHNP-BC.

Ethics declarations

Conflict of Interest

Peggy El-Mallakh and Jan Findlay declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Schizophrenia and Other Psychotic Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Mallakh, P., Findlay, J. Improving Treatment Adherence in Schizophrenia. Curr Treat Options Psych 3, 119–132 (2016). https://doi.org/10.1007/s40501-016-0074-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40501-016-0074-9

Keywords

Search

Navigation